Genotype frequency of plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism in healthy Japanese males and its relation to PAI-1 levels

International Journal of Hematology

Volumn 69, Issue 1, 1999, Pages 43-47

  Matsubara, Yumiko ^a   Murata, Mitsuru ^a   Isshiki, Ikuko ^a   Watanabe, Reiko ^a   Zama, Takeru ^a   Watanabe, Gentaro ^b   Watanabe, Kiyoaki ^a   Ikeda, Yasuo ^a  

^a KEIO UNIVERSITY   (Japan)

^b Health Center   (Japan)

Author keywords

4G 5G; Japanese; Plasminogen activator inhibitor 1; Polymorphism; Triglyceride

Indexed keywords

CHOLESTEROL; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD; BLOOD PRESSURE; BODY MASS; ETHNOLOGY; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HUMAN; JAPAN; MALE; MIDDLE AGED; POINT MUTATION; RISK; THROMBOPHILIA;

ADULT; BLOOD PRESSURE; BODY MASS INDEX; CHOLESTEROL; GENE FREQUENCY; GENOTYPE; HUMANS; JAPAN; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; POINT MUTATION; POLYMORPHISM, GENETIC; RISK; THROMBOPHILIA; TRIGLYCERIDES;

EID: 0032599948     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Wiman B. Plasminogen activator inhibitor 1 (PAI-1) in plasma: its role in thrombotic disease. Thromb Haemost 1995;74:71-6.
2. Juhan-Vague I, Valadier J, Alessi MC, et al. Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis. Thromb Haemost 1987;57:67-72.
3. Hamsten A, Wiman B, de Faire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 19853;13:1557-0.
4. Auwerx J, Bouillon R, Collen D, Geboers J. Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis 1988;8:68-72.
5. Eriksson P, Kallin B, van's Hooft FM, Båvenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A 1995;92:1851-5.
6. Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney AM. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 1993;268:10739-45.
7. Ye S, Green FR, Scarabin PY, et al. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Thromb Haemost 1995;74:837-41.
8. Panahloo A, Mohamed-Ali V, Lane A, Green F, Humphries SE, Yudkin JS. Determinants of plasminogen activator inhibitor 1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor 1 gene. Diabetes 1995;44:37-42.
9. Manfield MW, Stickland MH, Grant PJ. Environmental and genetic factors in relation to elevated circulating levels of plasminogen activator inhibitor-1 in Caucasian patients with non-insulin-dependent diabetes mellitus. Thromb Haemost 1995;74:842-7.
10. Henry M, Chomiki N, Scarabin PY, et al. Five frequent polymorphisms of the PAI-1 gene. Arterioscler Thromb Vase Biol 1997;17:851-8.
11. Stiko-Rahm A.Wiman B, Hamsten A, Nilsson J. Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein. Arteriosclerosis 1990;10:1067-73.
12. Hong Y, Pedersen NL, Egberg N, Faire U. Moderate genetic influences on plasma levels of plasminogen activator inhibitor-1 and evidence of genetic and environmental influences shared by plasminogen activator inhibitor-1, triglycerides, and body mass index. Arterioscler Thromb Vase Biol 1997;17:2776-82.
13. Ossei-Gerning N, Mansfield MW, Stickland MH, Wilson IJ, Grant PJ. Plasminogen activator inhibitor-1 promoter 4G/5G genotype and plasma levels in relation to a history of myocardial infarction in patients characterized by coronary angiography. Arterioscler Thromb Vase Biol 1997;17:33-7.
14. Eriksson P, Nilsson L, Karpe F, Hamsten A. Very-low-density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia. Arterioscler Thromb Vase Biol 1998;18:20-6.
15. Thin N, Stafford DW. A general method for isolation of high molecular weight DNA from eukaryocytes. Nucleic Acid Res 1976; 3:2303-8.
16. Bosma PJ.van den Berg EA, Kooistra T, Siemieniak DR, Slightom JL. Human plasminogen activator inhibitor-1 gene. J Biol Chem 1988;263:9129-41.
17. Margaglione M, Grandone E, Cappucci G, et al. An alternative method for PAI-1 promoter polymorphism (4G/5G) typing. Thromb Haemost 1997;77:605-6.
18. Margaglion M, Cappucci G, Colalzzo D, et al. The PAI-1 gene locus 4G/5G polymorphism is associated with a family history of coronary artery disease. Arterioscler Thromb Vase Biol 1998;18:152-156.
19. Manfield MW, Stickland MH, Grant PJ. Plasminogen activator inhibitor-1 (PAI-1) promoter polymorphism and coronary artery disease in non-insulin-dependent diabetes. Thromb Haemost 1995; 74:1032-4.
20. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Miletich JP. Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of plasminogen activator inhibitor gene in a large cohort of US men. Circulation 1997;95:59-62.
21. Burzotta F, Di Castelnuovo A, Amore C, D'Orazio A, Donati MB, Iacoviello L. 4G/5G polymorphism in the promoter region of the PAI-1 gene is not a risk factor for familial myocardial infarction in subjects over 45 years. Thromb Haemost 1997;78:1294-5.
22. Loskutoff DJ, Samad F. The adipocyte and hemostatic balance in obesity studies of PAI-1. Arterioscler Thromb Vase Biol 1998;18:l-6.
23. Shimomura I, Funahashi T. Takahashi M, et al. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nature Med 1996;2:800-3.